COMBINING EARLY IMMUNE INTERVENTION WITH ANTIFIBROTIC THERAPY

Traditional therapies for interstitial lung diseases focus on treating the fibrotic end stage, once irreversible lung damage has already occurred.  At A.D.A., we take a different approach by intervening early — at the origin of the disease. It is increasingly recognized that many ILDs have an autoimmune component driving their pathogenesis. Although the exact cause of idiopathic pulmonary fibrosis (IPF) remains unknown, there is an increasing amount of evidence showing that early immune-mediated inflammation triggers fibrosis. Our strategy targets these early inflammatory signals to prevent fibrosis progression. By modulating immune responses prior to the cascade leading to fibrosis, we aim to reduce fibrotic changes, preserving lung function and improving patient outcomes, offering a promising alternative to conventional therapies for complex pulmonary conditions.

Our innovative “Drug AND Delivery” platform not only modulates the underlying immune response, but uniquely offers the capability to incorporate an antifibrotic molecule within the same delivery system. This dual-action approach allows us to address simultaneously the autoimmune trigger and its fibrotic manifestations, ultimately preserving lung function and improving patients’ lives.